SI2844637T1 - Substituirani 3-haloalilaminski inhibitorji SSAO in njihova uporaba - Google Patents

Substituirani 3-haloalilaminski inhibitorji SSAO in njihova uporaba Download PDF

Info

Publication number
SI2844637T1
SI2844637T1 SI201331052T SI201331052T SI2844637T1 SI 2844637 T1 SI2844637 T1 SI 2844637T1 SI 201331052 T SI201331052 T SI 201331052T SI 201331052 T SI201331052 T SI 201331052T SI 2844637 T1 SI2844637 T1 SI 2844637T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
disease
alkyl
Prior art date
Application number
SI201331052T
Other languages
English (en)
Inventor
Mandar Deodhar
Alison Dorothy Findlay
Jonathan Stuart Foot
Wolfgang Jarolimek
Ian Alexander Mcdonald
Alan Robertson
Craig Ivan Turner
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of SI2844637T1 publication Critical patent/SI2844637T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/26—Thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (18)

  1. Substituirani 3-haloalilaminski inhibitorji SSAO in njihova uporaba Patentni zahtevki
    1. Spojina s formulo II:
    Formula II ali farmacevtsko sprejemljiva sol, solvat ali polimorfna oblika le-te; kjer: R5 je nesubstituirana fenilenska skupina ali fenilenska skupina, substituirana z eno ali več skupinami, neodvisno izbranimi izmed alkila, halo, alkoksi in haloalkila; R6 je izbran izmed:
    7 S R in R sta neodvisno izbrana iz skupine, ki jo sestavljajo vodik, po izbiri substituiran Ci.6alkil in po izbiri substituiran C3.7cikloalkil; in X je kisik;
    kjer se izraz "alkil" nanaša na monovalentne ravnoverižne ali razvejene nasičene ogljikovodikove ostanke, ki imajo 1-6 atomov ogljika, in kjer se izraz "halo" nanaša na fluor, klor, brom in jod, in kjer se izraz "alkoksi" nanaša na ravnoverižne ali razvejene alkiloksi skupine, kjer je alkil, kot je definirano prej, in kjer izraz "po izbiri substituiran(a)" pomeni, da je skupina, na katero se ta izraz nanaša, lahko nesubstituirana ali je lahko substituirana z eno ali več skupinami, neodvisno izbranimi izmed halogena, Ci-C6alkila, C2-C6alkenila, Ci-C6haloalkila, Ci-C6alkoksi, hidroksi(Ci.6)alkila, C3-C6cikloalkila, C(O)H, C(O)OH, NHC(O)H, NHC(O)CrC4alkila, C(O)CrC4alkila, NH2, NHCrC4alkila, N(CrC4alkila)2, NO2, OH in CN.
  2. 2. Spojina po zahtevku 1, kjer je R5 nesubstituirana fenilenska skupina ali fenilenska skupina, substituirana z eno ali več skupinami, neodvisno izbranimi izmed metila, fluora, klora, broma, OCH3 in CF3.
  3. 3. Spojina po katerem koli od zahtevkov 1 ali 2, kjer sta R7 in R8 oba vodik, R7 in R8 sta oba C i.6alkil ali je R7 vodik in je R8 Ci^alkil.
  4. 4. Spojina po katerem koli od zahtevkov 1-3, kjer je R6:
    kjer sta R7 in R8 definirana v zahtevku 1 ali 3.
  5. 5. Spojina po katerem koli od zahtevkov 1-3, kjer je R6:
    7 2 kjer sta R in R definirana v zahtevku 1 ali 3.
  6. 6. Spojina po zahtevku 1, kjer je spojina izbrana iz skupine, ki jo sestavljajo:
    ali farmacevtsko sprejemljiva sol ali solvat le-teh.
  7. 7. Spojina po zahtevku 1, kjer je spojina (£)-4-(2-(aminometil)-3-fluoroaliloksi)-/V-terc.-butilbenzamid ali farmacevtsko sprejemljiva sol ali solvat le-tega.
  8. 8. Farmacevtsko sprejemljiva sol spojine po katerem koli od zahtevkov 1-7.
  9. 9. Farmacevtsko sprejemljiva sol po zahtevku 8, označena s tem, da je kislinska adicijska sol.
  10. 10. Farmacevtsko sprejemljiva sol po zahtevku 9, označena s tem, da je kislinska adicijska sol izbrana iz skupine, ki jo sestavljajo hidrokloridi, hidrobromidi, sulfati, formiati, acetati, laktati malati, tartrati, citrati, askorbati, sukcinati, maleati, butirati, valerati in fumarati.
  11. 11. Farmacevtsko sprejemljiva sol po zahtevku 10, označena s tem, daje kislinska adicijska sol hidrokloridna sol.
  12. 12. Farmacevtsko sprejemljiva sol po zahtevku 11, pri čemer je farmacevtsko sprejemljiva sol hidroklorid (£)-4-(2-(aminometil)-3-fluoroaliloksi)-2V-ierc.-butilbenzamida.
  13. 13. Sestavek, ki obsega spojino po katerem koli od zahtevkov 1-7 ali farmacevtsko sprejemljivo sol po katerem koli od zahtevkov 8-12 ali slovat le-te in vsaj en farmacevtsko sprejemljiv ekscipient, nosilec ali razredčilo.
  14. 14. Spojina po katerem koli od zahtevkov 1-7 ali farmacevtsko sprejemljiva sol po katerem koli od zahtevkov 8-12 ali slovat le-te za uporabo pri postopku zdravljenja bolezni, povezane ali modulirane s proteinom SSAO/VAP-1, ki obsega dajanje individuumu, ki to potrebuje, terapevtsko učinkovite količine spojine ali farmacevtsko sprejemljive soli ali slovata le-te, kjer je bolezen vnetje, fibroza, bolezen, inducirana z diabetesom, nevroinflamatoma bolezen ali rak.
  15. 15. Spojina ali farmacevtsko sprejemljiva sol ali solvat za uporabo po zahtevku 14, kjer je vnetje povezano z jetrno boleznijo, respiratorno boleznijo, cistično fibrozo, astmo ali kronično obstrukcijsko pljučno boleznijo ali očesno boleznijo.
  16. 16. Spojina ali farmacevtsko sprejemljiva sol ali solvat za uporabo po zahtevku 14, kjer je bolezen bolezen, inducirana z diabetesom, izbrana iz skupine, ki jo sestavljajo diabetična nefropatija, glomeruloskleroza, diabetična retinopatija, nealkoholna zamaščenost jeter in horoidna neovaskularizacija.
  17. 17. Spojina ali farmacevtsko sprejemljiva sol ali solvat za uporabo po zahtevku 14 kjer je bolezen izbrana iz skupine, ki jo sestavljajo cistična fibroza, jetrna fibroza, jetrna ciroza, ledvična fibroza, skleroderma, idiopatična pljučna fibroza in fibroza, inducirana z radiacijo.
  18. 18. Spojina ali farmacevtsko sprejemljiva sol ali solvat za uporabo po zahtevku 17, označena s tem, da je bolezen nealkoholna zamaščenost jeter, nealkoholni steatohepatitis (NASH) ali bolezen, inducirana z alkoholom, ki vodi do ciroze jeter.
SI201331052T 2012-05-02 2013-04-05 Substituirani 3-haloalilaminski inhibitorji SSAO in njihova uporaba SI2844637T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641814P 2012-05-02 2012-05-02
EP13784562.4A EP2844637B1 (en) 2012-05-02 2013-04-05 Substituted 3-haloallylamine inhibitors of ssao and uses thereof
PCT/AU2013/000356 WO2013163675A1 (en) 2012-05-02 2013-04-05 Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Publications (1)

Publication Number Publication Date
SI2844637T1 true SI2844637T1 (sl) 2018-07-31

Family

ID=49514094

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331052T SI2844637T1 (sl) 2012-05-02 2013-04-05 Substituirani 3-haloalilaminski inhibitorji SSAO in njihova uporaba

Country Status (25)

Country Link
US (4) US9302986B2 (sl)
EP (2) EP2844637B1 (sl)
JP (3) JP6182595B2 (sl)
KR (2) KR102089935B1 (sl)
CN (2) CN107266332B (sl)
AU (2) AU2013255103B2 (sl)
BR (1) BR112014027406B1 (sl)
CA (2) CA2871793C (sl)
CY (1) CY1120334T1 (sl)
DK (1) DK2844637T5 (sl)
ES (1) ES2668300T3 (sl)
HK (2) HK1203477A1 (sl)
HR (1) HRP20180953T1 (sl)
HU (1) HUE038437T2 (sl)
LT (1) LT2844637T (sl)
ME (1) ME03063B (sl)
MX (1) MX360634B (sl)
NO (1) NO2842608T3 (sl)
PL (1) PL2844637T3 (sl)
PT (1) PT2844637T (sl)
RS (1) RS57086B1 (sl)
SG (2) SG11201406948PA (sl)
SI (1) SI2844637T1 (sl)
TR (1) TR201807453T4 (sl)
WO (1) WO2013163675A1 (sl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668300T3 (es) * 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
JP2018076236A (ja) * 2015-06-05 2018-05-17 株式会社アールテック・ウエノ がんを処置するための医薬組成物
AU2016366635A1 (en) 2015-12-07 2018-06-21 Benevolentai Cambridge Limited VAP-1 inhibitors for treating pain
KR20180119582A (ko) * 2016-02-12 2018-11-02 파맥시스 엘티디 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
US20210212968A1 (en) * 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
CN108341752B (zh) * 2017-01-21 2022-12-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
WO2018148856A1 (en) * 2017-02-14 2018-08-23 Eli Lilly And Company Diazaspirodecanyl-pyrimidine compounds useful as ssao inhibitors
NZ755847A (en) 2017-03-01 2021-12-24 Boehringer Ingelheim Int Transition metal-catalyzed protodecarboxylation of α-halo-acrylic acid derivatives
CN110709385A (zh) * 2017-03-02 2020-01-17 法玛西斯有限公司 赖氨酰氧化酶的卤代烯丙胺吡唑衍生物抑制剂及其用途
WO2018196677A1 (zh) * 2017-04-28 2018-11-01 四川科伦博泰生物医药股份有限公司 氟代烯丙胺衍生物及其用途
WO2018219982A1 (en) * 2017-05-31 2018-12-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
GB201709136D0 (en) * 2017-06-08 2017-07-26 Proximagen Ltd New therapeutic uses of enzyme inhibitors
WO2018233633A1 (zh) 2017-06-20 2018-12-27 南京明德新药研发股份有限公司 Ssao 抑制剂
CN109251166B (zh) * 2017-07-13 2021-11-05 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN110914234B (zh) * 2017-08-04 2023-06-23 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN109810041B (zh) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
CN109988106B (zh) * 2017-12-29 2023-03-31 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其在医药上的应用
KR20190110740A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
AU2019238090A1 (en) 2018-03-22 2020-10-08 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
MX2021001347A (es) * 2018-08-03 2021-04-13 Pharmaxis Ltd Inhibidores derivados de haloalilamina sulfona de lisil oxidasas y sus usos.
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) * 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
CA3114166A1 (en) * 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
JP2022511374A (ja) * 2018-09-28 2022-01-31 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
WO2020086747A2 (en) * 2018-10-24 2020-04-30 Metacrine, Inc. Ssao inhibitors and uses thereof
US20210353608A1 (en) * 2018-10-29 2021-11-18 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
AU2019373306A1 (en) 2018-10-29 2021-04-08 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
AU2019394947A1 (en) * 2018-12-05 2021-06-24 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
PE20211770A1 (es) 2018-12-14 2021-09-07 Yuhan Corp 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que las comprenden
AU2019408509B2 (en) 2018-12-20 2022-02-10 Shandong Danhong Pharmaceutical Co., Ltd. Process route of compound of formula (IV), crystal form and preparation method therefor
US20220081439A1 (en) 2019-01-11 2022-03-17 TransThera Sciences (Nanjing), Inc Haloallylamine compounds and application thereof
WO2020233583A1 (zh) * 2019-05-20 2020-11-26 广东东阳光药业有限公司 抑制ssao/vap-1的异喹啉酮类化合物及其用途
WO2021012014A1 (en) * 2019-07-25 2021-01-28 Pharmaxis Ltd. Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
KR20220090553A (ko) * 2019-10-29 2022-06-29 에코진 (상하이) 컴퍼니, 리미티드 Ssao 억제제 및 그의 용도
CN114728925B (zh) * 2019-11-28 2023-12-08 广东东阳光药业股份有限公司 一种作为ssao/vap-1抑制剂的胺类衍生物及其用途
IL296816A (en) * 2020-03-25 2022-11-01 Terns Inc Treatment of respiratory disorders
CN111654920B (zh) * 2020-06-02 2022-03-11 重庆邮电大学 一种分布式能效子载波功率分配方法
CN115916337A (zh) * 2020-06-26 2023-04-04 法玛西斯有限公司 卤代烯丙基胺双胺氧化酶抑制剂
AU2021332217A1 (en) 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor
CN114621189B (zh) * 2020-12-14 2024-01-02 上海拓界生物医药科技有限公司 一种内酰胺类衍生物及其用途
CN114621190B (zh) * 2020-12-14 2023-12-05 上海拓界生物医药科技有限公司 一种烯丙基胺类衍生物及其用途
CN114621243B (zh) * 2020-12-14 2024-03-01 上海拓界生物医药科技有限公司 一种磺酰胺类衍生物及其用途
WO2024044813A1 (en) * 2022-08-29 2024-03-07 Pharmaxis Ltd. Novel selective inhibitors of lysyl oxidases

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4454158A (en) 1981-06-01 1984-06-12 Merrell Toraude Et Compagnie Allyl amine MAO inhibitors
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4699928A (en) 1984-07-13 1987-10-13 Merrell Dow Pharmaceuticals Inc. Fluoroallylamine derivatives
ZA855101B (en) * 1984-07-13 1986-05-28 Merrell Dow Pharma Fluoroallylaine derivatives
US4650907A (en) 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
AU2003259965A1 (en) 2002-08-20 2004-03-11 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
US20060025438A1 (en) 2004-02-25 2006-02-02 Salter-Cid Luisa M Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases
CN1921841A (zh) * 2004-02-25 2007-02-28 拉卓拉药物公司 用于治疗疾病的胺和酰胺类化合物
WO2007005737A2 (en) 2005-07-01 2007-01-11 Case Western Reserve University Amine oxidase inhibitors
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
BRPI0713200A2 (pt) 2006-07-19 2012-04-10 Osurf Ohio State University Res Foundation moduladores seletivos de receptores de androgênio, seus análogos e derivados, e seus usos
US20100210697A1 (en) 2007-10-19 2010-08-19 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
WO2009061830A1 (en) 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
NZ585528A (en) * 2007-11-21 2012-08-31 Pharmaxis Ltd Haloallylamine inhibitors of ssao/vap-1 and uses therefor
UA112154C2 (uk) 2009-09-08 2016-08-10 Біоті Терапіс Корп. Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
ES2668300T3 (es) * 2012-05-02 2018-05-17 Boehringer Ingelheim International Gmbh Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos

Also Published As

Publication number Publication date
CN107266332B (zh) 2020-07-24
RS57086B1 (sr) 2018-06-29
KR20200030126A (ko) 2020-03-19
AU2013255103B2 (en) 2016-09-29
EP2844637B1 (en) 2018-03-28
US9302986B2 (en) 2016-04-05
US20160244406A1 (en) 2016-08-25
EP2844637A1 (en) 2015-03-11
BR112014027406A2 (pt) 2017-06-27
AU2013203655A1 (en) 2013-11-21
KR20150014926A (ko) 2015-02-09
WO2013163675A1 (en) 2013-11-07
JP2017132767A (ja) 2017-08-03
MX360634B (es) 2018-11-12
MX2014013294A (es) 2015-05-08
CY1120334T1 (el) 2019-07-10
US9815782B2 (en) 2017-11-14
BR112014027406B1 (pt) 2020-09-24
ES2668300T3 (es) 2018-05-17
NO2842608T3 (sl) 2018-07-21
CA2871793C (en) 2020-09-15
CN104520268B (zh) 2017-05-24
HK1203477A1 (en) 2015-10-30
ME03063B (me) 2019-01-20
JP6182595B2 (ja) 2017-08-16
SG10201707020TA (en) 2017-10-30
DK2844637T3 (en) 2018-04-23
US20150158813A1 (en) 2015-06-11
PL2844637T3 (pl) 2018-09-28
SG11201406948PA (en) 2014-11-27
AU2013203655B2 (en) 2017-02-02
JP2020019810A (ja) 2020-02-06
US10160723B2 (en) 2018-12-25
HUE038437T2 (hu) 2018-10-29
CA3086105A1 (en) 2013-11-07
JP2015521167A (ja) 2015-07-27
EP3438087A1 (en) 2019-02-06
AU2013255103A1 (en) 2014-11-06
TR201807453T4 (tr) 2018-06-21
JP6602802B2 (ja) 2019-11-06
US20190071396A1 (en) 2019-03-07
HK1245237A1 (zh) 2018-08-24
PT2844637T (pt) 2018-04-17
HRP20180953T1 (hr) 2018-07-27
DK2844637T5 (en) 2018-08-13
KR102089935B1 (ko) 2020-03-18
LT2844637T (lt) 2018-05-10
US20180086698A1 (en) 2018-03-29
EP2844637A4 (en) 2015-12-09
CN107266332A (zh) 2017-10-20
CA2871793A1 (en) 2013-11-07
CN104520268A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
SI2844637T1 (sl) Substituirani 3-haloalilaminski inhibitorji SSAO in njihova uporaba
JP2015521167A5 (sl)
HRP20190500T1 (hr) Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina
IN2014MN01839A (sl)
NZ701290A (en) Pyrrolobenzodiazepines
BR112015004529A2 (pt) alcóxi pirazóis como ativadores de guanilato ciclase solúvel
MY193514A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1, 5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
JP2015537020A5 (sl)
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
BR112015001618A2 (pt) composições fungicidas
PH12014501732A1 (en) Fungicidal pyrazole mixtures
BR112013029240A2 (pt) derivados deuterados do ivacaftor
MD20150036A2 (ro) Analogi de 2'-cloro nucleozide pentru tratarea hepatitei virale C
EP2581376A4 (en) MATRIC ACID / MATRIN DERIVATIVES AND MANUFACTURING METHOD AND USES THEREOF
MX2014006366A (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
EA201000024A1 (ru) Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1
JP2015535847A5 (sl)
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
JP2016513696A5 (sl)
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
WO2010011811A4 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds
JP2013537240A5 (sl)
EA201101211A1 (ru) 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-l-гидроксиэтил)-8-гидроксихинолин-2(1h)-oh и его применение для лечения легочных заболеваний
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
SI2782922T1 (sl) Antibakterijski derivati tilosina in postopki za pripravo le-teh